According to a Bloomberg article, I-Mab is in wide-ranging discussions with US and EU biopharmas for a deal that could out-license an I-Mab asset or involve a direct investment in the Shanghai biopharma. The potential investors were not named. One year ago, I-Mab announced a blockbuster $2 billion deal with AbbVie for global ex-China rights to I-Mab's anti-CD47 mAb. The agreement included options on two other anti-CD47 molecules for another billion dollars.  Simultaneously, I-Mab is planning a second IPO on Shanghai 's STAR board. More details.... Stock Symbols: (NSDQ: IMAB) (NYSE: ABBV) Share this with colleagues: // //